Welcome to our dedicated page for PharmaCyte Biotech SEC filings (Ticker: PMCB), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
PharmaCyte Biotech, Inc. filings document the company's public-company reporting, capital structure and governance as a Nasdaq-listed biotechnology issuer with common stock registered under PMCB. Recent disclosures include 8-K material-event reports, proxy statements for stockholder votes, equity incentive plan amendments, securities issuance authorizations, preferred stock and warrant financing terms, and notices related to periodic reporting.
The filings also document material agreements tied to external investments and capital deployment, alongside shareholder voting mechanics and security-structure disclosures for common stock, convertible preferred stock and warrants.
PharmaCyte Biotech, Inc. is a Nevada-based, development-stage biotechnology company developing cellular therapies for cancer using its cellulose-based Cell-in-a-Box encapsulation platform; its current product candidate, CypCaps, targets locally advanced, inoperable, non-metastatic pancreatic cancer.
The lead LAPC program remains under an FDA clinical hold on a 2020 Investigational New Drug application. Regulators requested extensive additional nonclinical, manufacturing and device-compatibility work. PharmaCyte and its partners report completing key stability, genetic-sequencing, biocompatibility and toxicity studies, while other mechanical and delivery-system tests continue, alongside active dialogue with the FDA.
Strategic risk is high. All licensed patents on the core technology have expired, know-how resides with SG Austria, and the board has curtailed development spending while a Scientific Committee reassesses programs and the SG Austria relationship. Austrianova is the sole manufacturer and has experienced supply-chain delays and possible liquidity constraints. The company had two employees as of April 30, 2026, relies heavily on consultants, holds orphan drug status for its pancreatic cancer therapy, and reported $6,278,282 in non-affiliate equity market value and 10,735,649 common shares outstanding.
WALKER WAYNE REMELL reported acquisition or exercise transactions in this Form 4 filing.
PharmaCyte Biotech, Inc. director Wayne Remell Walker reported an administrative correction to a prior stock option grant. The footnote explains that the grant was made in error and has been cancelled, leaving 0.0000 derivative securities from this grant and no common stock bought or sold.
Abecassis Michael M reported acquisition or exercise transactions in this Form 4 filing.
PharmaCyte Biotech, Inc. director Michael M. Abecassis reported an amended insider transaction dated 2026-03-31 involving a stock option classified as a derivative security.
The amendment states the previously reported grant was made in error and has been cancelled, with 0.0000 shares and 0.0000 derivative holdings shown after this correction.
SCHECHTER JONATHAN reported acquisition or exercise transactions in this Form 4 filing.
PharmaCyte Biotech director Jonathan Schechter filed an amended insider report for a stock option (right to buy) entry dated March 31, 2026. A footnote explains that the reported grant was made in error and has been cancelled, leaving 0 options from this grant outstanding.
WEINSTEIN ROBERT reported acquisition or exercise transactions in this Form 4 filing.
PharmaCyte Biotech, Inc. director Robert Weinstein reported a correction to a stock option award. A previously reported Stock Option (Right to Buy) grant dated 2026-03-31 was made in error and has been cancelled, leaving 0 derivative shares transacted and 0 shares remaining from that specific grant.
PharmaCyte Biotech, Inc. reported that director Robert Weinstein received a grant of stock options covering 119,170 shares of common stock. The options have an exercise price of $0.67 per share, were awarded at no cost, and expire on March 30, 2036. They will vest in full on the date of the company’s next annual meeting of stockholders, subject to his continued service.
PharmaCyte Biotech, Inc. director Wayne Remell Walker received a grant of stock options covering 119,170 shares of common stock. The options have an exercise price of $0.67 per share and expire on March 30, 2036, with 119,170 derivative securities held after this grant.
According to the filing, the options will vest in full on the date of the company’s next annual meeting of stockholders, subject to Mr. Walker’s continued service. This award is characterized as a grant or other acquisition of derivative securities rather than an open-market purchase.
PharmaCyte Biotech director Jonathan Schechter received a grant of stock options for 119,170 shares of Common Stock. The options have a $0.67 exercise price, expire on March 30, 2036, and were awarded as compensation, not an open-market purchase. They vest in full at the issuer's next annual stockholder meeting, subject to his continued service, leaving him with 119,170 options following this grant.
PharmaCyte Biotech, Inc. director Michael M. Abecassis received a grant of stock options covering 119,170 shares of common stock. The options have an exercise price of $0.67 per share and expire on March 30, 2036. According to the terms, the options vest in full on the date of the company’s next annual meeting of stockholders, subject to his continued service.
PharmaCyte Biotech, Inc. reported results of its annual stockholder meeting held by webcast. Stockholders approved all five proposals, including an amendment to the 2022 Equity Incentive Plan that increases the shares of common stock available for awards by 2,000,000.
Five directors were elected to serve until the next annual meeting, each receiving over 3.3 million votes in favor, with broker non-votes recorded. Stockholders also ratified CBIZ CPAs P.C. as independent auditor for the fiscal year ending April 30, 2026.
Investors approved, on a non-binding advisory basis, the compensation of the named executive officers. They further authorized the board, but did not require it, to implement a reverse stock split of the outstanding common stock at any ratio between 1-for-1.1 and 1-for-100.